NICE Clinical Knowledge Summaries: Tiredness/Fatigue in adults (includes CFS).

The lack of response to a very cogent letter such as this would, in its way, be a tacit response in itself. Should any enquiries ever be instigated in the future, a very deliberate lack of response might be interpreted as showing a clear inability to sensibly answer the questions without risk of incrimination.
 
Trial By Error: Tack and I Write to Psych Medicine; Struthers Writes to Medical Research Council

"Caroline Struthers–a self-described “citizen scientist and patient-directed research enthusiast” who comments on twitter as @healthy_control–has been relentless in pushing Cochrane to be more transparent about the acknowledged problems with these reviews. Thanks to her persistence, Cochrane recently revamped its pages to make its own advisories about the reviews more visible to readers. Now she has taken the logical step of pointing out these and other recent developments to Professor Watt, in light of her 2018 defense of PACE."

https://www.virology.ws/2021/07/24/...struthers-writes-to-medical-research-council/
 

Attachments

Last edited:
I have now written to Matt Westmore Chief Exec of the HRA (https://www.hra.nhs.uk/about-us/who-we-are/our-board-members/matt-westmore/) copying in Carol Monaghan from the Science and Technology Select Committee. I had an out of office from Matt Westmore who is away until 9 August.

Edit - and posted on blog https://healthycontrol.org/2021/07/27/letter-to-health-research-authority-re-pace-trial-july-2021/
According to Matt Westmore's presentation page:

Matt has held roles with the National Institute for Health Research (NIHR) including as an executive director of the Evaluation Trials and Studies Coordinating Centre (NETSCC). He was also Interim Director of INVOLVE and as a member of the HRA’s Research Transparency Strategy Group, he supported the development of the organisation’s Make it Public strategy for research transparency.
Unlike Prof Sir Montgomery, who specializes in healthcare law, Westmore has direct experience with clinical trials and he seems to advocate for research transparency. Hopefully, he is in a better position to hear the arguments on publicly releasing data from the PACE trial -- especially the long delayed, as yet unfulfilled promise from the MRC --.

Thank you for your continued involvement, @Caroline Struthers.

ETA: on the other hand, Sir Terence Stephenson chairs the HRA, and he is close to Esther Crawley -- he heads the CLoCK study on pediatric long Covid, of which she is a principal investigator. I do not know whether Stephenson is Westmore's hierarchical superior -- the first is a non-executive director of the HRA's board, the second an executive director --, but a conflict of interest does not seem to be out of the realm of possibilities.
 
Last edited:
I have now written to Matt Westmore Chief Exec of the HRA (https://www.hra.nhs.uk/about-us/who-we-are/our-board-members/matt-westmore/) copying in Carol Monaghan from the Science and Technology Select Committee. I had an out of office from Matt Westmore who is away until 9 August.

Edit - and posted on blog https://healthycontrol.org/2021/07/27/letter-to-health-research-authority-re-pace-trial-july-2021/
The PACE authors played incredibly hard to get, as we know, for release of data from the previous FOI request, and it was very clear why they did that, given how analysis of that data exposed so much about their amateurish science. So it doesn't need a lot of insight to understand why they are playing so very hard to get again this time, with releasing the remaining data.

I'll bet they know full well there is further damning evidence lurking in there, perhaps much more damning than the first time around. Basically they are cr*pping themselves, and the only strategy they know (and are so well practiced at) is to sit tight, do nothing, deny everything, and stick their fingers up at everyone - patients, good scientists, etc. They dare not let that data be released if they can possibly avoid it, I'm pretty sure. I very much doubt it will happen without a further FOI request, and one that is very carefully worded to pre-empt every possible cheap excuse they are likely to come up with. It's the nature of the beast.
 
According to Matt Westmore's presentation page:

Matt has held roles with the National Institute for Health Research (NIHR) including as an executive director of the Evaluation Trials and Studies Coordinating Centre (NETSCC). He was also Interim Director of INVOLVE and as a member of the HRA’s Research Transparency Strategy Group, he supported the development of the organisation’s Make it Public strategy for research transparency.
Unlike Prof Sir Montgomery, who specializes in healthcare law, Westmore has direct experience with clinical trials and he seems to advocate for research transparency. Hopefully, he is in a better position to hear the arguments on publicly releasing data from the PACE trial -- especially the long delayed, as yet unfulfilled promise from the MRC --.

Thank you for your continued involvement, @Caroline Struthers.

ETA: on the other hand, Sir Terence Stephenson chairs the HRA, and he is close to Esther Crawley -- he heads the CLoCK study on pediatric long Covid, of which she is a principal investigator. I do not know whether Stephenson is Westmore's hierarchical superior -- the first is a non-executive director of the HRA's board, the second an executive director --, but a conflict of interest does not seem to be out of the realm of possibilities.
Since I sent the email i have been shown that the data from PACE is available via the CSDR portal, although not publicly of course. https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20098. I couldn't find it with a keyword search. Also Matt W has already replied to me saying they will consider and respond soon. Despite an "out of office until 9 August" auto-reply! I didn't know about the Sir Terence connection with Esther Crawley though...
 
Since I sent the email i have been shown that the data from PACE is available via the CSDR portal, although not publicly of course. https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20098. I couldn't find it with a keyword search.
From that link, what is the difference between the "raw dataset", which is not available, and the "analysis-ready dataset", which is available? Is the latter simply an anonymized version of the first? Or can the latter have been post-processed by the authors so it is only ready for the sort of analyses they would feel more comfortable with others making? i.e. Frigged to the point of uselessness? How can anyone ever be confident that the authors' do not obfuscate data of their own choosing, as part of the same operation to anonymize the data. What independent oversight is there on that process?

upload_2021-7-27_17-42-53.png

Edit: Is this how the PACE authors' have got around their coyness to share the data, versus the commitment to do so? Shared it but tried not to tell anyone?

Edit 2: Just realised the "ready to share" box is not ticked. Is that what is actually blocking availability of the data?
 
Last edited:
I have now written to Matt Westmore Chief Exec of the HRA (https://www.hra.nhs.uk/about-us/who-we-are/our-board-members/matt-westmore/) copying in Carol Monaghan from the Science and Technology Select Committee. I had an out of office from Matt Westmore who is away until 9 August.

Edit - and posted on blog https://healthycontrol.org/2021/07/27/letter-to-health-research-authority-re-pace-trial-july-2021/
Great letter. Maybe my memory fails me but I don't remember a mention of Peter White clearly having resumed his work using this data and how his retirement was an "excuse" for not doing what we know for a fact was actually prepared in advance, as shown by the minutes.

Certainly worth mentioning. It's one thing to use obviously BS excuses but even worse when they don't even bother adhering to them.
 
From that link, what is the difference between the "raw dataset", which is not available, and the "analysis-ready dataset", which is available? Is the latter simply an anonymized version of the first? Or can the latter have been post-processed by the authors so it is only ready for the sort of analyses they would feel more comfortable with others making? i.e. Frigged to the point of uselessness? How can anyone ever be confident that the authors' do not obfuscate data of their own choosing, as part of the same operation to anonymize the data. What independent oversight is there on that process?

View attachment 14520

Edit: Is this how the PACE authors' have got around their coyness to share the data, versus the commitment to do so? Shared it but tried not to tell anyone?
Good spot!
 
I'll bet they know full well there is further damning evidence lurking in there, perhaps much more damning than the first time around. Basically they are cr*pping themselves, and the only strategy they know (and are so well practiced at) is to sit tight, do nothing, deny everything, and stick their fingers up at everyone - patients, good scientists, etc. They dare not let that data be released if they can possibly avoid it, I'm pretty sure. I very much doubt it will happen without a further FOI request, and one that is very carefully worded to pre-empt every possible cheap excuse they are likely to come up with. It's the nature of the beast.
Someone should suggest that the GRADE system (and any other such tools) automatically should rate any research that doesn't provide open access to its raw data, as 'very low'. Wonder how that would affect future research and future Cochrane reports....
 
I have now written to Matt Westmore Chief Exec of the HRA (https://www.hra.nhs.uk/about-us/who-we-are/our-board-members/matt-westmore/) copying in Carol Monaghan from the Science and Technology Select Committee. I had an out of office from Matt Westmore who is away until 9 August.

Edit - and posted on blog https://healthycontrol.org/2021/07/27/letter-to-health-research-authority-re-pace-trial-july-2021/

Interesting, in the response to AQW UIN 33370 the Minister for DWP stated that:
"The National Institute for Health Research (NIHR) and UK Research and Innovation (UKRI) have invested in research into myalgic encephalomyelitis, chronic fatigue syndrome and ‘long’ COVID-19. All research commissioned by the NIHR and UKRI is subject to robust peer review processes to ensure that all the studies funded use appropriate outcome criteria to assess and measure their impact."
[https://members.parliament.uk/member/4827/writtenquestions#expand-1341754]


The Science and Technology Committee scrutinises*, in particular, the Department for Business, Energy and Industrial Strategy - who fund UKRI. So [EDIT - Carol Monaghan MP] should be in a position to challenge what's been funded by UKRI - I assume this Committee can also scrutinise NIHR funding and MRC.

*
"The Science and Technology Committee exists to ensure that Government policy and decision-making are based on good scientific and engineering advice and evidence.

The Science and Technology Committee is unusual amongst departmental select committees in that it scrutinises the Government Office for Science (GO-Science), which is a "semi-autonomous organisation" based within the Department for Business, Energy and Industrial Strategy.

GO-Science "supports the Government Chief Scientific Adviser and works to ensure that Government policy and decision-making is underpinned by robust scientific evidence". The committee therefore has a similarly broad remit and can examine the activities of departments where they have implications for, or made use of, science, engineering, technology and research."
https://committees.parliament.uk/committee/135/science-and-technology-committee/role/
https://committees.parliament.uk/committee/135/science-and-technology-committee/role/
 
Last edited:
Referring to the quote from the letter in post #24

"the CKS do not represent formal NICE guidance.”

This was used against me by a GP some years ago when I was trying to get help for my hypothyroidism. He said (I'm paraphrasing because I've forgotten the exact words) that the Clinical Knowledge Summaries were viewed by doctors as nonsense and nobody followed their recommendations. They used other guidelines (which were unspecified).
 
Since I sent the email i have been shown that the data from PACE is available via the CSDR portal, although not publicly of course. https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20098. I couldn't find it with a keyword search. Also Matt W has already replied to me saying they will consider and respond soon. Despite an "out of office until 9 August" auto-reply! I didn't know about the Sir Terence connection with Esther Crawley though...
I have now heard back from Fiona Watt who has updated me on "data-gate". The data is no longer available via CSDR portal, which explains why I couldn't find it. It has been transferred - see letter below and attached

Dear Caroline,

Thank you for your email of 19th July regarding the PACE trial. I agree with you that the landscape has changed since my letter to the Times back in 2018, not least because we have funded new research into the potential link between genetics and ME/CFS (DecodeME) and because of emerging concerns about Long Covid.

You asked specifically why the anonymised data from the PACE trial had not been included in the Clinical Study Data Request (CSDR) portal. In fact, The PACE trial data has been available to request since November 2019, firstly via the CSDR web portal during a pilot which ran until March 2021. Following this pilot, the dataset listing was transferred to the Vivli portal where it is now available on request via the Vivli independent Review Panel. MRC has paid for the listing to be permanently accessible on Vivli. The review panel is independent of the trial investigators, sponsor and funders. Details of how to apply for access to the dataset can be found here whilst the dataset listing can be found here. Please note that MRC was not involved in the anonymization process, which was undertaken by the investigators.

I do hope that this update is helpful.


With best wishes,
 

Attachments

Referring to the quote from the letter in post #24

"the CKS do not represent formal NICE guidance.”

This was used against me by a GP some years ago when I was trying to get help for my hypothyroidism. He said (I'm paraphrasing because I've forgotten the exact words) that the Clinical Knowledge Summaries were viewed by doctors as nonsense and nobody followed their recommendations. They used other guidelines (which were unspecified).
I need to chase NICE about this as they have not responded to my emails.
 
I have now heard back from Fiona Watt who has updated me on "data-gate". The data is no longer available via CSDR portal, which explains why I couldn't find it. It has been transferred - see letter below and attached

Dear Caroline,

Thank you for your email of 19th July regarding the PACE trial. I agree with you that the landscape has changed since my letter to the Times back in 2018, not least because we have funded new research into the potential link between genetics and ME/CFS (DecodeME) and because of emerging concerns about Long Covid.

You asked specifically why the anonymised data from the PACE trial had not been included in the Clinical Study Data Request (CSDR) portal. In fact, The PACE trial data has been available to request since November 2019, firstly via the CSDR web portal during a pilot which ran until March 2021. Following this pilot, the dataset listing was transferred to the Vivli portal where it is now available on request via the Vivli independent Review Panel. MRC has paid for the listing to be permanently accessible on Vivli. The review panel is independent of the trial investigators, sponsor and funders. Details of how to apply for access to the dataset can be found here whilst the dataset listing can be found here. Please note that MRC was not involved in the anonymization process, which was undertaken by the investigators.

I do hope that this update is helpful.


With best wishes,
Ah, yes, the old strategy of "we have made this available in secret for years you should have just asked about it specifically". Very credible and not shady at all.

I got curious about "the letter" and basically most of what has changed is that everything she said has been found to be either partially false or completely discredited, all the evidence has been found to be of low quality and the findings of PACE were massively misrepresented:
Fiona Watt in 2018 said:
Sir, Further to your report “Call for review of ‘flawed’ ME research”(Aug 21), as funders of the Pace trial we reject the view that the scientific evidence provided by the trial for using cognitive behavioural theory and managed exercise in the treatment of chronic fatigue syndrome (also known as ME) was unsound. The Pace trial was funded following expert peer review, was overseen by an independent steering committee, and its published findings have also been independently peer-reviewed. Other research groups have drawn similar conclusions. Chronic fatigue syndrome/ME remains a priority for the Medical Research Council (MRC), and it is important that researchers are not discouraged from working on the disease because of concerns that they could be subject to the level of hostility that Pace researchers have experienced. Medical research can only flourish when there is mutual respect between all parties.
The "hostility" of course being legitimate criticism that has been fully validated. This person has no credibility here.
 
I have now heard back from Fiona Watt who has updated me on "data-gate". The data is no longer available via CSDR portal, which explains why I couldn't find it. It has been transferred - see letter below and attached

Dear Caroline,

Thank you for your email of 19th July regarding the PACE trial. I agree with you that the landscape has changed since my letter to the Times back in 2018, not least because we have funded new research into the potential link between genetics and ME/CFS (DecodeME) and because of emerging concerns about Long Covid.

You asked specifically why the anonymised data from the PACE trial had not been included in the Clinical Study Data Request (CSDR) portal. In fact, The PACE trial data has been available to request since November 2019, firstly via the CSDR web portal during a pilot which ran until March 2021. Following this pilot, the dataset listing was transferred to the Vivli portal where it is now available on request via the Vivli independent Review Panel. MRC has paid for the listing to be permanently accessible on Vivli. The review panel is independent of the trial investigators, sponsor and funders. Details of how to apply for access to the dataset can be found here whilst the dataset listing can be found here. Please note that MRC was not involved in the anonymization process, which was undertaken by the investigators.

I do hope that this update is helpful.


With best wishes,
I got curious about "the letter" and basically most of what has changed is that everything she said has been found to be either partially false or completely discredited, all the evidence has been found to be of low quality and the findings of PACE were massively misrepresented:

upload_2021-7-28_17-8-35.png

The "hostility" of course being legitimate criticism that has been fully validated. This person has no credibility here.
The difference in tone is significant, both in magnitude and implication. Much more conciliatory this time, much less arrogant/belligerent. Interesting to ponder why? I think it shows folk know the writing is on the wall.
Fiona Watt said:
I agree with you that the landscape has changed since my letter to the Times back in 2018
Indeed it has, especially the way long-time promoters of cr*p science may be feeling the need to abandon a sinking ship and switch sides.
 
Last edited:
Back
Top Bottom